Pfizer, GSK US RSV Vaccine Uptake Likely Hurt By ACIP’s Weaker Recommendation

Price tag, inadequate trial designs, safety and questions about possibility of boosters were among the reasons CDC advisors voted that adults 60 and over ‘may’ receive an RSV vaccine. A stronger ‘should’ receive RSV vaccine had seemed possible for the over 65 group earlier this year.

senior citizen talking to doctor — CDC’s ACIP recommended shared decision making for RSV vaccines for older adults. • Source: Shutterstock

GSK plc and Pfizer Inc. will likely have to work harder than they anticipated to get older adults vaccinated with the sponsors’ newly approved respiratory syncytial virus (RSV) vaccines following a US Centers for Disease Control and Prevention advisory committee’s lukewarm reception of the products on 21 June.

The CDC’s Advisory Committee on Immunization Practices voted 9-5 that adults 65 years of age and older may receive a...